Gyre Therapeutics Investor Relations Material
Latest events
Q2 2025
11 Aug, 2025
Q1 2025
9 May, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Gyre Therapeutics Inc
Access all reports
Gyre Therapeutics Inc., formerly known as Catalyst Biosciences, Inc., is a biopharmaceutical company engaged in the development and commercialization of therapies for organ fibrosis and inflammatory diseases. The company's main focus is on the development of Hydronidone (F351), a therapeutic aimed at treating Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis), previously known as Nonalcoholic Steatohepatitis (NASH). The company is headquartered in San Diego, California, and its shares are listed on the NASDAQ.
Key slides for Gyre Therapeutics Inc
H.C. Wainwright 27th Annual Global Investment Conference
Gyre Therapeutics Inc
H.C. Wainwright 27th Annual Global Investment Conference
Gyre Therapeutics Inc
Latest articles
)
Stephen J. Squeri: American Express Veteran Chairman and CEO
Stephen Squeri has spent over four decades at American Express, rising through the ranks to lead one of the world's most recognized brands.
15 Sep 2025
)
Where to? The Story of Uber
Uber's journey from rule-breaking disruptor to disciplined dual-app giant, now shaping the future of mobility, delivery, and autonomy.
5 Sep 2025
)
The Dilemma That Brought Down Kodak
Kodak helped invent digital photography but failed to embrace it. How the innovator's dilemma turned an icon into its own most famous casualty.
21 Aug 2025
Ticker symbol
GYRE
Country
🇺🇸 United States